Novo Nordisk requests FDA to halt unapproved Ozempic, Wegovy compounding due to safety concerns.
Novo Nordisk has requested the FDA to stop compounding pharmacies from making unapproved versions of its diabetes treatment Ozempic and weight-loss drug Wegovy, citing safety concerns. The company argues that semaglutide, the active ingredient, is too complex to be safely replicated and should be added to the FDA's list of drugs that should not be compounded. This move follows ongoing issues with compounded versions that pose risks to patient safety. The FDA is reviewing the request.
October 23, 2024
21 Articles